CRIS News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

CR

Mkt Cap

$1.2M

Volume

1.31M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Lift Therapeutics Appoints Daniel Passeri as Chief Executive OfficerLift Therapeutics announced the appointment of Daniel Passeri as CEO, bringing over 30 years of oncology drug development experience. Bo Rode Hansen transitions from Interim CEO to President and Board member. The company is preparing to advance its lead immuno-Modulatory Alpha Neutrophil (iMAN) program into first-in-human clinical studies in early 2027.GlobeNewswire Inc. · Sep 23, 2026

Curis (CRIS) Q4 2025 Earnings Call TranscriptCuris reported Q4 2025 net income of $19.4 million ($1.23 per share) driven by a $27.2 million one-time gain from selling Erivedge to Oberland. The company has eliminated legacy revenue streams and is now focused on advancing its TakeAim Lymphoma (PCNSL) registrational study and initiating a CLL proof-of-concept study. With $20.2 million in PIPE financing received in January 2026 and potential additional $20.2 million upon CLL milestone achievement, the company expects to fund operations into 2027. Early AML triplet therapy data showed five of eight evaluable patients achieved MRD conversion.The Motley Fool · Mar 19, 2026

Curis (CRIS) Q2 Loss Narrows 66%Biotechnology company Curis reported a narrowed Q2 2025 net loss of $0.68 per share, beating analyst expectations. The company continues advancing its cancer therapy emavusertib while facing near-term funding challenges, with cash reserves expected to last only into Q1 2026.The Motley Fool · Aug 5, 2025

VISTA Inhibitor Clinical Trials Drug Approval Insight - GlobeNewswireVISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from existing therapies.GlobeNewswire Inc. · Jul 11, 2024

Top 3 Health Care Stocks That May Collapse In Q2As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above ...Benzinga · Apr 12, 2024

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.Zacks Investment Research · Apr 5, 2024

CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For FridayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Telsey Advisory Group raised the price target for Ralph Lauren Corporation (NYSE: RL) from $165 to $195. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Ralph Lauren shares jumped 16.8% to close at $171.85 on Thursday. See how other analysts view this stock. HSBC cut Bunge Global SA (NYSE: BG) price target from $122 to $105. HSBC analyst Wesley Brooks upgraded the stock from Hold to Buy. Bunge Global shares fell 1.7% to close at $86.50 on Thursday. See how other analysts view this stock. Jefferies boosted the price target for Inotiv, Inc. (NASDAQ: NOTV) from $3 to $11.5. Jefferies analyst David Windley upgraded the stock from Hold to Buy. Inotiv shares gained 16.8% ...Full story available on Benzinga.comBenzinga · Feb 9, 2024

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionShares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Getaround, Inc. (NYSE: GETR) shares jumped 151.3% to $0.4618 after the company announced a new debt facility with Mudrick Capital Management for up to $20 million. Evaxion Biotech A/S (NASDAQ: EVAX) gained 94.4% to $9.70 after a 13G filing showed Merck & Co reported an 11.4% stake in the company as of Dec. 21, 2023. SciSparc Ltd. (NASDAQ: SPRC) shares gained 61.3% to $5.58 after the company revealed $20 million standby equity purchase agreement. Kura Oncology, Inc. (NASDAQ: KURA) rose 41.3% to $18.99. Kura Oncology announced oversubscribed $150 million private placement. Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares jumped 32.2% to $1.8372. Ensysce Biosciences shares gained 22% on Tuesday after the company announced FDA Breakthrough Therapy Designation for PF614-MPAR. RedHill Biopharma Ltd. (NASDAQ: RDHL) climbed 25.5% to $1.1197. Redhill Biopharma was granted U.S. Patent #11878011 for "Method for Eradicating Helicobacter Pylori Infection in Patients Regardless of Body Mass Index." Purple Innovation, Inc. (NASDAQ: PRPL) gained 24% to $1.02 after the company announced it strengthened its balance sheet, creating greater financial flexibility to execute its ...Benzinga · Jan 24, 2024

Why Dolby Laboratories Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day SessionShares of Dolby Laboratories, Inc. (NYSE: DLB) fell during Friday’s session following weak guidance. Dolby Laboratories reported quarterly earnings of 65 cents per share, surpassing the analyst consensus estimate of 53 cents. The company reported quarterly sales of $290.56 million, which topped the analyst consensus estimate of $290.20 million, according to data from Benzinga Pro. Dolby Laboratories said it sees first-quarter earnings between 80 cents and 95 cents per share, versus the $1.08 estimate. The company sees total revenue in a range between $300 million and $330 million, versus the estimate of $353.67 million. Dolby Laboratories shares dropped 8.3% to $80.49 Here are some other stocks moving in today's mid-day session. Gainers Altamira Therapeutics Ltd. (NASDAQ: CYTO) surged 183% to $0.2830. Altamira Therapeutics announced partial spin-off of Bentrio business. Safe and Green Development Corporation (NASDAQ: SGD) shares jumped 141% to $7.33. Safe And Green Development shares jumped around 559% on Thursday after the company said it does not intend to conduct the offering of the shares of common stock contemplated by the Registration Statement. WANG & LEE GROUP, Inc. (NASDAQ: WLGS) shares gained 76.5% to $0.7097. Mural Oncology plc (NASDAQ: MURA) shares gained 41.2% to $5.35 after falling around 92% on Thursday. Curis, Inc. (NASDAQ: CRIS) jumped 36.5% to $8.07. Truist Securities initiated coverage on Curis with a Buy rating and announced a price target of $26. Syntec Optics Holdings, Inc. (NASDAQ: OPTX) shares gained 33% to $6.90 after gaining around 12% on Thursday. Syntec Optics was awarded a contract for optics in biomedical equipment. The Gap, Inc. (NYSE: GPS) gained 26.9% to $17.35 after ...Benzinga · Nov 17, 2023

Curis shares rise as analysts see 'the next Pharmacyclics'Shares of Curis rose premarket Friday as analysts see biotech company as potential take-out targetMarketWatch · Nov 17, 2023

CR

CRISCuris Inc

CRIS

Pay with—

Available Balance0.00

Your PositionYou don't own any CRIS yet.

Related Tickers

Earnings